PURE Bioscience Raises \$1 Million Through Private Placement Financing

Key Highlights

• PURE Bioscience, Inc. completed a private placement financing on April 30, 2026, raising \$1.0 million from accredited investors.
• The company issued a total of 18,131,096 shares of common stock at a price of \$0.0553 per share.
• The shares were issued pursuant to a Securities Purchase Agreement with the investors, including participation by a member of the Board of Directors, Mr. Tom Y. Lee.
• The securities were sold in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
• Proceeds from the sale will be used for working capital and general corporate purposes.
• This capital raise could have a material impact on the company’s liquidity position and may influence future operational and strategic decisions.

Detailed Overview

PUR Bioscience, Inc., the creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, has announced the successful completion of a private placement financing round. This transaction resulted in the company raising \$1,000,000, which was secured through the issuance of 18,131,096 shares of common stock to a group of accredited investors at a price per share of \$0.0553.

The shares were issued under a Securities Purchase Agreement entered into with the investors. The agreement contains standard provisions, including representations, warranties, covenants, and indemnification obligations. Notably, Mr. Tom Y. Lee, a current member of the Board of Directors, participated in this investment round, signaling internal confidence in the company’s prospects.

The shares issued in this private placement are restricted securities and were not registered under the Securities Act of 1933. They may not be offered or sold in the United States without registration or a valid exemption. The company relied on the private placement exemption under Section 4(a)(2) and Rule 506 of Regulation D. All participating investors represented that they are “accredited investors” as defined in Rule 501 of Regulation D and acquired the shares for investment purposes only, not for resale.

Additionally, the company has filed a Form 8-K to disclose the material terms of the transaction and will file a Form D with the SEC, as required. The company also confirmed that the shares were issued in full compliance with federal and state securities laws and that no further approval or authorization from shareholders or the board is required for this issuance.

Potentially Price-Sensitive and Shareholder-Impacting Information

• Dilution: The issuance of over 18 million new shares will result in dilution to existing shareholders.
• Insider Participation: The participation of a board member in the financing round may be seen as a positive indicator of management’s confidence in the company’s future.
• Use of Proceeds: The company plans to use the funds for working capital and general corporate purposes, which may help stabilize operations and support ongoing business activities.
• Financial Position: The successful capital raise enhances PURE Bioscience’s liquidity and may provide runway for further growth, product development, or strategic initiatives.
• No Registration: Since the shares are restricted, they will not be immediately available for trading on public markets, potentially limiting immediate liquidity impacts but setting the stage for future developments.

Additional Investor Considerations

• The company made standard representations regarding its capitalization, compliance with reporting requirements, and the absence of material adverse changes or undisclosed liabilities since its last audited financial statements.
• No brokerage or finder’s fees were paid in connection with this transaction, and the company confirmed that it is not an “investment company” under the Investment Company Act of 1940.
• PUR Bioscience has agreed to use commercially reasonable efforts to maintain the listing or quotation of its common stock on the current trading market.
• The company will keep a sufficient number of shares reserved to fulfill the terms of this and any similar agreements.

Conclusion

This private placement financing is a significant event for PURE Bioscience, Inc., providing much-needed capital and signaling internal confidence through board member participation. While the capital raise strengthens the company’s financial position, the dilution from the new share issuance and the restricted nature of the securities are important factors for current and prospective investors to consider. This event may impact the share price, depending on market perceptions of dilution versus improved liquidity and insider confidence.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult financial advisors before making investment decisions. The information presented is based on the company’s public filings and may be subject to change or clarification by the company or regulatory authorities.

View PURE BIOSCIENCE, INC. Historical chart here